Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Arcutis Biotherapeutics ( (ARQT) ) has provided an update.
On December 3, 2025, Bhaskar Chaudhuri retired from Arcutis Biotherapeutics‘ Board of Directors, transitioning to a consulting role. Concurrently, Amit Munshi was appointed as a new director and chair of the Compensation Committee, bringing extensive biopharmaceutical leadership experience to support Arcutis’ growth and commercialization efforts.
The most recent analyst rating on (ARQT) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Arcutis Biotherapeutics stock, see the ARQT Stock Forecast page.
Spark’s Take on ARQT Stock
According to Spark, TipRanks’ AI Analyst, ARQT is a Neutral.
Arcutis Biotherapeutics’ overall score is driven by strong earnings call results and positive technical indicators, despite challenges in financial performance and valuation. The company’s strategic initiatives and pipeline expansions position it well for future growth, but current profitability and cash flow issues remain significant concerns.
To see Spark’s full report on ARQT stock, click here.
More about Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing innovative treatments for immune-mediated dermatological diseases. The company offers a range of advanced targeted topicals for major inflammatory skin diseases, leveraging its dermatology development platform to create differentiated therapies.
Average Trading Volume: 2,331,750
Technical Sentiment Signal: Buy
Current Market Cap: $3.82B
Learn more about ARQT stock on TipRanks’ Stock Analysis page.